Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus Pharmaceuticals (NASDAQ: TARS) has initiated enrollment in the Saturn-2 pivotal trial for TP-03, a novel treatment for Demodex blepharitis, affecting up to 25 million Americans. This follows the successful completion of enrollment in the Saturn-1 trial with 421 participants, with topline results expected this July. TP-03 targets Demodex mites with a topical formulation, and if successful, may lead to the first FDA-approved treatment for this condition. With no current approved therapies, the need for effective solutions is significant.

Tarsus Pharmaceuticals has announced that the FDA accepted its Investigational New Drug (IND) application for TP-05, a novel oral therapy aimed at preventing Lyme disease. This significant milestone allows the company to start a Phase 1 study focusing on safety and pharmacokinetics in July 2021. Lyme disease affects over 300,000 Americans annually, and TP-05 could be the first approved non-vaccine therapeutic. Tarsus is also exploring TP-05 for malaria prevention, while continuing clinical trials for its lead product candidate, TP-03.

Tarsus Pharmaceuticals announced significant findings from the Atlas study, highlighting that Demodex blepharitis affects approximately 25 million Americans, with 80% of patients reporting a negative impact on daily life. Tarsus' lead candidate, TP-03, has shown promising Phase 2b efficacy and safety results, paving the way for pivotal Saturn-1 and Saturn-2 trials. The Europa study confirmed TP-03's effectiveness, achieving an 80% collarette cure rate. Tarsus aims to advance its clinical program, addressing the substantial psychosocial burdens caused by this condition.

Tarsus Pharmaceuticals (NASDAQ: TARS) announced that its CEO, Bobak Azamian, will present at the BofA Securities 2021 Virtual Health Care Conference on May 12 at 5:00 PM ET. The presentation aims to provide an overview of Tarsus' innovative approach to eye care and its lead product TP-03, which is in a pivotal Phase 2b/3 trial for treating Demodex blepharitis. Live webcasts will be accessible on their investor relations page and available for 90 days.

For further inquiries, contact SuJin Oh at Shop PR.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced the completion of enrollment for its first pivotal trial, Saturn-1, for TP-03 targeting Demodex blepharitis. A strategic partnership with LianBio is set to provide $70 million within the next 12 months and up to $130 million later, alongside royalties and equity. Tarsus reported a net loss of $26.8 million in 2020, with cash reserves totaling $168 million. The company is also advancing pipeline programs TP-04 and TP-05, focusing on unmet medical needs. The FDA confirmed the NDA pathway for TP-03 following a Type C meeting in December 2020.

Tarsus Pharmaceuticals has partnered with LianBio to enhance the reach of its investigational treatment TP-03 for Demodex blepharitis and Meibomian Gland Disease in China, affecting up to 100 million patients. This strategic alliance includes an upfront payment of $15 million and potential milestone payments totaling $185 million. TP-03, currently in pivotal clinical trials, aims to address the unmet medical need for these conditions. Tarsus anticipates this collaboration will bolster its pipeline and expand its global market presence.

Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Dr. Bryan Wahl as General Counsel. With over 15 years of legal experience, including expertise in intellectual property and corporate transactions, Dr. Wahl will support Tarsus in expanding its product pipeline, such as TP-03 for Demodex blepharitis. Previously a partner at Knobbe Martens LLP, he has been advising Tarsus since its foundation. Tarsus aims to transform treatments for poorly managed diseases, particularly in eye care.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced the appointment of Dianne Whitfield as Chief Human Resources Officer. With over 20 years of HR experience and a strong background in the life sciences industry, Whitfield joins from Evolus, where she supported the commercialization of its first product. Her leadership aims to foster organizational growth and innovation within Tarsus. CEO Bobak Azamian expressed enthusiasm for her expertise in building effective teams and a positive culture at a pivotal time for the company as it advances its pipeline.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that CEO Bobak Azamian will present at the ICR Conference 2021, scheduled for January 11-14. The presentation will take place on January 14 at 2:30 PM ET. Tarsus aims to develop breakthrough treatments for poorly treated diseases, with a focus on eye care. Their lead product, TP-03, is currently in Phase 2b/3 trials for Demodex blepharitis. Investors can access the live webcast and will have the option to replay it for 90 days.